Navigation Links
First Published Clinical Study Successfully Uses Precision Medicine To Predict Prescription Opioid Abuse
Date:4/19/2017

IRVINE, Calif., April 19, 2017 /PRNewswire/ -- As a Bronze Sponsor of the National Rx Drug Abuse and Heroin SummitProove® Biosciences, Inc. announces the first-ever peer-reviewed published clinical study analyzing genetics, environmental, and lifestyle factors to accurately predict prescription opioid abuse. In this study, researchers from the University of Southern California (USC), the Interventional Pain Institute in Baltimore, and Proove publish results showing that Proove Opioid Risk® accurately identifies patients at risk for Opioid Use Disorder (OUD).

This study, An Observational Study to Calculate Additive Risk to Opioids: A Validation Study of a Predictive Algorithm to Evaluate Opioid Use Disorder (O.S.C.A.R.), is published in the international peer-reviewed journal, Pharmacogenomics and Personalized Medicine (Impact Factor: 4.21). In this trial, researchers evaluated 908 pain patients using opioids, 258 subjects with OUD versus 650 controls. The O.S.C.A.R. study demonstrates that Proove Opioid Risk® is a precision medicine technology that successfully stratifies patient risk. Compared to "low" risk patients, "moderate" and "high" risk patients had increased odds of OUD (4.17-fold and 16.5-fold, respectively, with 95.7% sensitivity). .

"This study suggests that Proove Opioid Risk® is more accurate than questionnaires like the SOAPP-R in identifying patients who abuse opioids. It's an excellent tool useful in guiding responsible pain treatment," explains study author Dr. Maneesh Sharma, Medical Director of the Interventional Pain Institute in Baltimore. 

Dr. Svetlana Kantorovich, Proove®'s R&D Director explains, "This is the first of many peer-reviewed publications over the next several months demonstrating the validity of Proove Opioid Risk®, building on the existing published evidence for each algorithm component."

Study author, Dr. Steven Richeimer, Director of USC's Pain Management Center and Associate Clinical Professor at the USC Keck School of Medicine, explains, "Precision medicine can potentially help physicians choose more effective treatments (similar to targeted cancer therapies), decrease iatrogenic addictions and overdoses by prescreening patients, and possibly even aid in the diagnosis of pain conditions."

Proove Opioid Risk® is a proprietary precision medicine profile consisting of an algorithm which analyzes 17 variables (11 genetic and 6 lifestyle and behavioral factors) individually supported by over 30 peer-reviewed publications correlated with narcotic addiction and related behaviors. Balancing these factors (42% genetic and 58% non-genetic), Proove Opioid Risk® may assist in solving the prescription drug abuse epidemic.

About Proove® Biosciences: Proove® Biosciences is the leader in precision medicine for the condition that lies at the nexus of health – pain. Proove® delivers precision medicine solutions for the nation's most prevalent and expensive health condition by investing heavily in research that has won awards from leading medical societies and been published in peer-reviewed journals.  Discovered by NIH-funded scientists, Proove® has translated into clinical practice the genetic variants and phenotypic factors contributing to pain sensitivity and chronic pain risk. Proove®'s medical advisory board is led by those NIH-funded researchers and the company has licensed some of its technology from leading academic centers such as the University of North Carolina at Chapel Hill. Positioned as The Healthcare Decision Company,™ Proove®'s patented technology platform combines genetic, clinical, environmental and lifestyle information to help clinicians better evaluate pain sensitivity, assess risk for opioid use disorder, predict therapeutic response to pain medications, and assess drug metabolism for the many medications used in chronic pain patients. Based in Irvine, CA. Proove® is recognized on the Inc. 500 and the Deloitte Fast500 as one of the fastest growing companies in NA. For more information, please visit www.proove.com or call toll free 855-PROOVE-BIO (855-776-6832).

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/first-published-clinical-study-successfully-uses-precision-medicine-to-predict-prescription-opioid-abuse-300441884.html


'/>"/>
SOURCE Proove Biosciences, Inc.
Copyright©2017 PR Newswire.
All rights reserved


Related biology technology :

1. Veracyte to Host Conference Call and Webcast to Discuss First Quarter 2017 Financial Results on Wednesday, May 3, 2017
2. SENOMYX, INC. FIRST QUARTER 2017 EARNINGS CONFERENCE CALL SCHEDULED FOR APRIL 27, 2017
3. The Worth Group Unveils First Health and Wellness Summit
4. Neurocrine Announces FDA Approval of INGREZZA TM (valbenazine) Capsules as the First and Only Approved Treatment for Adults with Tardive Dyskinesia (TD)
5. Halozyme To Host First Quarter 2017 Financial Results Conference Call
6. Startup, Job-type Comparisons Made for First Time in Annual Photonics Salary Report
7. 2-Day Seminar FDAs GMP Expectations for Phase I and First-in-Man Clinical Trials by Ex-FDA Official (Tampa, FL, United States - May 18-19, 2017) - Research and Markets
8. Research and Markets - Frontier Pharma Report: Head and Neck Cancer Market 2017 - Immunotherapies and Signal Transduction Inhibitors Dominate First-in-Class Innovation
9. 23andMe, Inc. Granted First FDA Authorization to Market Direct-to-Consumer Genetic Health Risk Reports
10. Watershed Idea Foundry Acquires Additive Innovations and Names First CEO
11. Exact Sciences to host first-quarter 2017 results webcast and call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2017)... ... April 21, 2017 , ... ... nourishing a range of emerging bio and technology start-ups, is hosting “Celebration Friday” ... This double event will start with libations and networking at 3:30 p.m. at ...
(Date:4/20/2017)... -- Eli Lilly and Company (NYSE: LLY ) ... prevention of migraine at the American Academy of Neurology ... 2017, in Boston . ... safety and patient outcomes data for galcanezumab in patients ... monthly migraine headache days among patients with episodic migraine. ...
(Date:4/20/2017)... Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("Prometic" or the ... ("ILC") 2017 of the European Association for the Study of ... the positive effects of PBI-4050 on reduction of non-alcoholic steatohepatitis ... ... Gagnon, Vice-President of R&D Pre-clinical of Prometic "This extensive preclinical ...
(Date:4/20/2017)... 20, 2017 Dutch philosopher Koert van Mensvoort - ... the University of Technology in Eindhoven - has written a ,Letter to ... calls on humanity to avoid becoming a slave and victim to its own ... ... Dutch philosopher Koert van Mensvoort – founder of the Next Nature Network ...
Breaking Biology Technology:
(Date:4/13/2017)... , April 13, 2017 UBM,s Advanced ... will feature emerging and evolving technology through ... Innovation Summits will run alongside the expo portion of ... sessions, panels and demonstrations focused on trending topics within ... advanced design and manufacturing event will take place June ...
(Date:4/11/2017)... April 11, 2017 No two people ... at the New York University Tandon School of ... have found that partial similarities between prints are ... in mobile phones and other electronic devices can ... The vulnerability lies in the fact that fingerprint-based ...
(Date:4/5/2017)... 5, 2017 Today HYPR Corp. , ... server component of the HYPR platform is officially ... end-to-end security architecture that empowers biometric authentication across Fortune ... already secured over 15 million users across the financial ... connected home product suites and physical access represent a ...
Breaking Biology News(10 mins):